Acumen Pharmaceuticals (ABOS) Non-Current Assets (2021 - 2026)

Acumen Pharmaceuticals has disclosed Non-Current Assets across 6 years of filings, most recently posting $494000.0 for Q2 2026.

• In Q2 2026, Non-Current Assets fell 97.9% year-over-year to $494000.0; the TTM figure through Jun 2026 stood at $11.7 million (down 93.95% YoY), while the FY2025 annual figure was $581000.0, down 99.04% from the prior year.
• Non-Current Assets came in at $494000.0 for Q2 2026 at Acumen Pharmaceuticals, down from $535000.0 in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $67.8 million in Q3 2023 to a low of $494000.0 in Q2 2026.
• Average Non-Current Assets over 5 years is $30.0 million, with a median of $25.7 million recorded in 2023.
• Year-over-year, Non-Current Assets jumped 9526.85% in 2023 and plunged 99.04% in 2025.
• Over 5 years, Non-Current Assets stood at $16.3 million in 2022, then jumped by 290.64% to $63.5 million in 2023, then fell by 4.45% to $60.7 million in 2024, then slumped by 99.04% to $581000.0 in 2025, then declined by 14.97% to $494000.0 in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $494000.0 in Q2 2026, $535000.0 in Q1 2026, and $581000.0 in Q4 2025.